Comments
Panacea Biotec on Thursday announced the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAlI, a single-dose live-attenuated tetravalent vaccine.
According to the World Health Organization, Dengue represents one of the ten biggest global health threats, and we must have access to a safe and effective vaccine candidate that can reduce the devastating impact of Dengue fever in endemic regions.
The shares are trading at a day's high of Rs 198.15, rising up to 4.98 per cent.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.